

INSUPPORT™ was created by Indivior to help streamline the access and reimbursement processes on behalf of patients seeking treatment with SUBLOCADE (buprenorphine extended-release). INSUPPORT provides information for healthcare professionals (HCPs) and their offices in support of these patients, including:



HUB SERVICES

- Verification of patient health insurance benefits and estimated out-of-pocket costs
- Provision of prior authorization (PA) requirements from the patient's health insurance provider
- Confirmation of product acquisition requirements from the patient's health insurance provider
- Determination of patient copay assistance eligibility*



FIELD REIMBURSEMENT SPECIALIST

A local specialist to provide the following to office staff:

- In-person support
- Explanation of patient insurance benefits and requirements
- Information about INSUPPORT services
- Billing and drug coding information for Indivior's products



INSUPPORT WEBSITE www.insupport.com

- Find information about the steps in the patient access process
- Learn more about the INSUPPORT Copay Assistance Program for SUBLOCADE*
- Access the Provider Portal to allow electronic enrollment and case monitoring
- Access tools, informational videos, and other resources
- Locate a Field Reimbursement Specialist

* The INSUPPORT Copay Assistance Program is valid ONLY for patients with private insurance who are prescribed SUBLOCADE for on-label use. Patients with government insurance are not eligible for the Copay Assistance Program, including, but not limited to, Medicare, Medicaid, Medigap, VA, DoD, TRICARE, CHAMPVA, or any other federally or state-funded government-assisted program. Other restrictions apply. Visit insupport.com to view complete Terms & Conditions.

For **BOXED WARNING**, refer to front page. See accompanying full Prescribing Information, including **BOXED WARNING** and Medication Guide, or go to www.sublocade.com.

For more information, call INSUPPORT at 844-INSPPRT (844-467-7778)
or visit www.insupport.com.

REFERENCES

1. Centers for Medicare & Medicaid Services. ICD-10-CM tabular list of diseases and injuries. https://www.cms.gov/medicare/coding/icd10/downloads/6_i10tab2010.pdf. Accessed March 9, 2018.
2. Sublocade [package insert]. North Chesterfield, VA: Indivior Inc; 2017.
3. American Medical Association. 2018 Professional Edition, Current Procedural Terminology (CPT). Copyright 2017 American Medical Association. 2018. All rights reserved.
4. Centers for Medicare & Medicaid Services. Pub 100-04 Medicare Claims Processing Transmittal 4048. Quarterly Healthcare Common Procedure Coding System (HCPCS) Drug/Biological Code Changes. July 2018 Update. May 11, 2018. <https://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/2018Downloads/R4048CP.pdf>. Accessed May 17, 2018.
5. Centers for Medicare & Medicaid Services. Medicare Learning Network. MLN Matters® Number: SE1234. September 5, 2012. Important information concerning the Medicare crossover process and state Medicaid agency requirements for National Drug Codes (NDCs) associated with physician-administered Part B drugs. <https://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNMattersArticles/downloads/se1234.pdf>. Accessed May 9, 2018.

Billing and Coding Guide for SUBLOCADE™ (buprenorphine extended-release)

WARNING: RISK OF SERIOUS HARM OR DEATH WITH INTRAVENOUS ADMINISTRATION; SUBLOCADE RISK EVALUATION AND MITIGATION STRATEGY

- Serious harm or death could result if administered intravenously. SUBLOCADE forms a solid mass upon contact with body fluids and may cause occlusion, local tissue damage, and thrombo-embolic events, including life threatening pulmonary emboli, if administered intravenously.
- Because of the risk of serious harm or death that could result from intravenous self-administration, SUBLOCADE is only available through a restricted program called the SUBLOCADE REMS Program. Healthcare settings and pharmacies that order and dispense SUBLOCADE must be certified in this program and comply with the REMS requirements.

See accompanying full Prescribing Information, including **BOXED WARNING** and Medication Guide, or go to www.sublocade.com.

Sublocade™
(buprenorphine extended-release)
injection for subcutaneous use Ⓢ
100mg-300mg

INTERNATIONAL CLASSIFICATION OF DISEASES (ICD)-10 CODES FOR OPIOID DEPENDENCE¹

SUBLOCADE (buprenorphine extended-release) is indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a transmucosal buprenorphine-containing product, followed by dose adjustment for a minimum of 7 days.

SUBLOCADE should be used as part of a complete treatment program that includes counseling and psychosocial support.

ICD-10 CODES	
F11.2	Opioid dependence
F11.20	Uncomplicated
F11.21	In remission
F11.22	Opioid dependence with intoxication
F11.220	Uncomplicated
F11.221	Delirium
F11.222	With perceptual disturbance
F11.229	Unspecified
F11.24	With opioid-induced mood disorder
F11.25	Opioid dependence with opioid-induced psychotic disorder
F11.250	With delusions
F11.251	With hallucinations
F11.259	Unspecified
F11.28	Opioid dependence with other opioid-induced disorder
F11.281	Opioid dependence with other opioid-induced sexual dysfunction
F11.282	Opioid dependence with other opioid-induced sleep disorder
F11.288	Opioid dependence with other opioid-induced disorder
F11.29	With unspecified opioid-induced disorder

The individual or entity submitting a claim using INSUPPORT reimbursement and coding information must ensure that all information submitted on or with the claim is accurate, complete, and applicable to the claim being filed.

The above listed codes are provided for informational, nonpromotional purposes only. Third-party coverage and reimbursement are complex and may change frequently. Providers are responsible for determining and submitting appropriate codes and charges and appropriate medical services and products in accordance with providers' independent professional judgment.

Indivior makes no representations or warranties or guarantees of any kind relating to access, coverage, or reimbursement.

The appropriateness of filing any particular claim is and remains the responsibility of that claim's submitter based on the submitter's own judgment.

NATIONAL DRUG CODES (NDCs) AND CURRENT PROCEDURAL TERMINOLOGY (CPT) CODE*

NDCs FOR SUBLOCADE (BUPRENORPHINE EXTENDED-RELEASE)²

NDC	MILLIGRAMS
12496-0100-01	100 mg
12496-0300-01	300 mg

CPT CODE³

CPT CODE	DESCRIPTION
96372	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular

SUBLOCADE should be administered by subcutaneous injection only. Do not administer SUBLOCADE intravenously or intramuscularly.

* CPT copyright 2018 American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association. The AMA assumes no liability for data contained or not contained herein.

The individual or entity submitting a claim using INSUPPORT reimbursement and coding information must ensure that all information submitted on or with the claim is accurate, complete, and applicable to the claim being filed.

The above listed codes are provided for informational, nonpromotional purposes only. The information provided is accurate on the publication date, but it should be independently verified.

The appropriateness of filing any particular claim is and remains the responsibility of that claim's submitter based on the submitter's own judgment.

Contact your Field Reimbursement Specialist for
more information or to schedule an in-office meeting.

Call INSUPPORT at **844-INSPPRT** (844-467-7778)
between 8:00 AM and 8:00 PM ET.

Visit www.insupport.com.

For **BOXED WARNING**, refer to front page. See accompanying full Prescribing Information, including **BOXED WARNING** and Medication Guide, or go to www.sublocade.com.

HEALTHCARE COMMON PROCEDURE CODING SYSTEM (HCPCS) CODES

PRODUCT-SPECIFIC HCPCS CODES FOR SUBLOCADE (BUPRENORPHINE EXTENDED-RELEASE)⁴

HCPCS CODE	DESCRIPTION	NUMBER OF UNITS	SITES OF CARE
Q9991	Injection, buprenorphine extended-release (Sublocade), less than or equal to 100 mg	1	<ul style="list-style-type: none"> • Physician office • Hospital outpatient clinic
Q9992	Injection, buprenorphine extended-release (Sublocade), greater than 100 mg	1	<ul style="list-style-type: none"> • Physician office • Hospital outpatient clinic

Q codes are primarily applicable to the physician office or hospital outpatient clinic settings.

Although Medicare requires the use of the Q-codes effective for dates of service on or after July 1, 2018, other payers may not immediately update their claims-processing systems with these codes. Therefore, it is important to confirm payer-specific coding requirements or contact INSUPPORT at 1-844-INSPPRT for assistance. Contact the insurance company before submission to obtain payer-specific information.

Please note that some payers, including state Medicaid programs, require HCPs to report the 11-digit HIPAA-compliant version of the NDC (5-4-2 format) for a physician-administered drug along with its HCPCS code on paper claim forms and their electronic equivalents.⁵

NDC FORMATTING ON MEDICAL CLAIMS

NDC	MILLIGRAMS	NDC FORMAT FOR CLAIMS	NDC LOCATION ON CLAIM FORMS
12496-0100-01	100 mg	N412496010001	<ul style="list-style-type: none"> • CMS-1500: Box 24A • CMS-1450: Field 42
12496-0300-01	300 mg	N412496030001	<ul style="list-style-type: none"> • CMS-1500: Box 24A • CMS-1450: Field 42

The individual or entity submitting a claim using INSUPPORT reimbursement and coding information must ensure that all information submitted on or with the claim is accurate, complete, and applicable to the claim being filed. The appropriateness of filing any particular claim is and remains the responsibility of that claim's submitter based on the submitter's own judgment. Contact the insurance company before submission to obtain payer-specific information.